(January 7, 2019, 1:18 PM EST) -- WASHINGTON, D.C. — The U.S. Supreme Court on Jan. 7 declined to rule on whether Daubert v. Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993), requires additional testing of a Depakote birth defect plaintiff to eliminate an alleged alternative cause claimed by defendant Abbott Laboratories (N.K., et al. v. Abbott Laboratories, No. 18-327, U.S. Sup.)....